| scholarly article | Q13442814 |
| P2093 | author name string | Sung-Soo Park | |
| Soo-Youl Kim | |||
| Dae-Seok Kim | |||
| In-Hoo Kim | |||
| Byung-Ho Nam | |||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | drug resistance | Q12147416 |
| P304 | page(s) | 10936-10943 | |
| P577 | publication date | 2006-11-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Reversal of drug resistance in breast cancer cells by transglutaminase 2 inhibition and nuclear factor-kappaB inactivation | |
| P478 | volume | 66 |
| Q38608634 | A novel mechanism by which tissue transglutaminase activates signaling events that promote cell survival |
| Q89972746 | A qualitative transcriptional prognostic signature for patients with stage I-II pancreatic ductal adenocarcinoma |
| Q39162858 | Anti-cancer effect of a quinoxaline derivative GK13 as a transglutaminase 2 inhibitor. |
| Q34449739 | Anti-inflammatory effects of the R2 peptide, an inhibitor of transglutaminase 2, in a mouse model of allergic asthma, induced by ovalbumin |
| Q36003028 | Ataxia-Telangiectasia, Mutated (ATM)/Nuclear Factor κ light chain enhancer of activated B cells (NFκB) signaling controls basal and DNA damage-induced transglutaminase 2 expression |
| Q35849327 | Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities |
| Q24304987 | Cancer cells promote survival through depletion of the von Hippel-Lindau tumor suppressor by protein crosslinking |
| Q35161277 | Cardamonin Suppresses TGF-β1-Induced Epithelial Mesenchymal Transition via Restoring Protein Phosphatase 2A Expression |
| Q30483685 | Clinical and biological significance of tissue transglutaminase in ovarian carcinoma |
| Q28384756 | Comparison of toxicogenomics and traditional approaches to inform mode of action and points of departure in human health risk assessment of benzo[a]pyrene in drinking water |
| Q28550149 | Compensatory Increase of Transglutaminase 2 Is Responsible for Resistance to mTOR Inhibitor Treatment |
| Q35604870 | Curcumin enhances the efficacy of chemotherapy by tailoring p65NFκB-p300 cross-talk in favor of p53-p300 in breast cancer |
| Q28249358 | Depletion of cathepsin D by transglutaminase 2 through protein cross-linking promotes cell survival |
| Q33667547 | EGF potentiated oncogenesis requires a tissue transglutaminase-dependent signaling pathway leading to Src activation |
| Q92963094 | Early differentiating between the chemotherapy responders and nonresponders: preliminary results with ultrasonic spectrum analysis of the RF time series in preclinical breast cancer models |
| Q36393086 | Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells |
| Q28478491 | Evidence that aberrant expression of tissue transglutaminase promotes stem cell characteristics in mammary epithelial cells |
| Q34269343 | GPR56 in cancer progression: current status and future perspective |
| Q42683546 | Increased TG2 expression can result in induction of transforming growth factor beta1, causing increased synthesis and deposition of matrix proteins, which can be regulated by nitric oxide |
| Q38852588 | Knockdown of NF-κB p65 subunit expression suppresses growth of nude mouse lung tumour cell xenografts by inhibition of Bcl-2 apoptotic pathway |
| Q33647335 | Maurocalcine as a non toxic drug carrier overcomes doxorubicin resistance in the cancer cell line MDA-MB 231 |
| Q35176934 | Novel 3-arylethynyl-substituted thieno[3,4-b]pyrazine derivatives as human transglutaminase 2 inhibitors. |
| Q43699421 | Novel MRI and fluorescent probes responsive to the Factor XIII transglutaminase activity |
| Q38888783 | Oxidative stress shapes breast cancer phenotype through chronic activation of ATM-dependent signaling |
| Q37665592 | PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis. |
| Q59794754 | Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition |
| Q35147626 | Role of tissue transglutaminase 2 in the acquisition of a mesenchymal-like phenotype in highly invasive A431 tumor cells. |
| Q34927039 | Simultaneously targeting tissue transglutaminase and kidney type glutaminase sensitizes cancer cells to acid toxicity and offers new opportunities for therapeutic intervention |
| Q36913614 | Targeting signaling pathways in epithelial ovarian cancer |
| Q36547077 | Targeting the Intracellular Environment in Cystic Fibrosis: Restoring Autophagy as a Novel Strategy to Circumvent the CFTR Defect |
| Q36884822 | The Different Conformational States of Tissue Transglutaminase Have Opposing Affects on Cell Viability. |
| Q64072854 | The GTP binding activity of transglutaminase 2 promotes bone metastasis of breast cancer cells by downregulating microRNA-205 |
| Q52728099 | The convergent roles of NF-κB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma. |
| Q87593562 | The diamond anniversary of tissue transglutaminase: a protein of many talents |
| Q33490653 | The mechanism of transglutaminase 2 inhibition with glucosamine: implications of a possible anti-inflammatory effect through transglutaminase inhibition |
| Q38294813 | The transglutaminase 2 gene (TGM2), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer |
| Q41903416 | The transglutaminase 2 gene is aberrantly hypermethylated in glioma |
| Q38161340 | Tissue Transglutaminase (TG2)-Induced Inflammation in Initiation, Progression, and Pathogenesis of Pancreatic Cancer |
| Q28475746 | Tissue Transglutaminase Promotes Drug Resistance and Invasion by Inducing Mesenchymal Transition in Mammary Epithelial Cells |
| Q39268578 | Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat. |
| Q26824316 | Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer |
| Q34489967 | Tissue transglutaminase constitutively activates HIF-1α promoter and nuclear factor-κB via a non-canonical pathway |
| Q37258496 | Tissue transglutaminase is an essential participant in the epidermal growth factor-stimulated signaling pathway leading to cancer cell migration and invasion |
| Q36916874 | Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling |
| Q36447849 | Tissue transglutaminase-interleukin-6 axis facilitates peritoneal tumor spreading and metastasis of human ovarian cancer cells |
| Q36503511 | Tissue transglutaminase: a new target to reverse cancer drug resistance |
| Q38065965 | Transglutaminase 2 and NF-κB: an odd couple that shapes breast cancer phenotype |
| Q39798025 | Transglutaminase 2 as a cisplatin resistance marker in non-small cell lung cancer |
| Q35387117 | Transglutaminase 2 as an independent prognostic marker for survival of patients with non-adenocarcinoma subtype of non-small cell lung cancer |
| Q37001622 | Transglutaminase 2 expression predicts progression free survival in non-small cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitor |
| Q35683575 | Transglutaminase 2 facilitates the distant hematogenous metastasis of breast cancer by modulating interleukin-6 in cancer cells |
| Q53288102 | Transglutaminase 2 gene ablation protects against renal ischemic injury by blocking constant NF-κB activation |
| Q38648421 | Transglutaminase 2 in cancer |
| Q93188555 | Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations |
| Q39017211 | Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models |
| Q34994693 | Transglutaminase 2 overexpression in tumor stroma identifies invasive ductal carcinomas of breast at high risk of recurrence |
| Q39029196 | Transglutaminase 2 reprogramming of glucose metabolism in mammary epithelial cells via activation of inflammatory signaling pathways. |
| Q35693361 | Transglutaminase 2: a molecular Swiss army knife |
| Q37224569 | Transglutaminase-2 Is Involved in All-Trans Retinoic Acid-Induced Invasion and Matrix Metalloproteinases Expression of SH-SY5Y Neuroblastoma Cells via NF-κB Pathway |
| Q92219315 | Transglutaminase-2 Mediates the Biomechanical Properties of the Colorectal Cancer Tissue Microenvironment that Contribute to Disease Progression |
| Q38937553 | Transglutaminase-2: evolution from pedestrian protein to a promising therapeutic target |
| Q38222985 | Transglutaminases: recent achievements and new sources |
Search more.